Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma - Trial NCT03952572
Access comprehensive clinical trial information for NCT03952572 through Pure Global AI's free database. This Phase 3 trial is sponsored by Peking University and is currently Recruiting. The study focuses on Peripheral T-cell Lymphoma. Target enrollment is 244 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Peking University
Timeline & Enrollment
Phase 3
May 10, 2019
Apr 30, 2023
Primary Outcome
Response rate
Summary
Primary objective of the study is to compare the efficacy and safety of CDOP versus CHOP for
 newly diagnosed peripheral T-cell lymphoma (PTCL).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT03952572
Non-Device Trial